Apnimed Inc. Common Stock (APMD)
Stock · NASDAQ · Health Care
$17.76as of 10/16/2026
Price chart
Active signals
No technical signal is currently active for this symbol.
Industry
Biotechnology: Pharmaceutical Preparations
About APMD
Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. It offers AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 81
- Website
- apnimed.com
Fundamentals
- 1-day range
- $18.31$20
- Market cap
- $1.06B
- P/E (trailing)
- —
- P/E (forward)
- -4.69
- EPS (trailing)
- —
- Dividend yield
- —
- Beta
- 0.95
- Avg. volume
- 541.6K
52-week range
$16.12$35.29
Next earnings: November 11, 2026 · EPS estimate $-0.60
Apnimed Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- APMDApnimed Inc. Common Stock$17.76▼ 2.68%Market cap $1.06BP/E —$16.12$35.29
- LXRXLexicon Pharmaceuticals Inc. Common Stock$1.52▼ 7.88%Market cap $1.05BP/E —$1.1$2.68
- OLMAOlema Pharmaceuticals Inc. Common Stock$6.58▼ 4.22%Market cap $1.03BP/E —$6.61$36.26
- JBIOJade Biosciences Inc. Common Stock$13.47▼ 2.11%Market cap $1.10BP/E —$8.36$28
- PCRXPacira BioSciences Inc. Common Stock$36.34▲ 0.03%Market cap $1.02BP/E 98.88$18.8$36.46
- IVAInventiva S.A. American Depository Shares$2.94▼ 5.47%Market cap $1.10BP/E —$2.57$6.2
- ANROAlto Neuroscience Inc. Common Stock$21.94▼ 3.01%Market cap $1.11BP/E —$5.23$37.48
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| APMD Apnimed Inc. Common Stock | $1.06B | — | $17.76 | ▼ 2.68% | $16.12$35.29 |
| LXRX Lexicon Pharmaceuticals Inc. Common Stock | $1.05B | — | $1.52 | ▼ 7.88% | $1.1$2.68 |
| OLMA Olema Pharmaceuticals Inc. Common Stock | $1.03B | — | $6.58 | ▼ 4.22% | $6.61$36.26 |
| JBIO Jade Biosciences Inc. Common Stock | $1.10B | — | $13.47 | ▼ 2.11% | $8.36$28 |
| PCRX Pacira BioSciences Inc. Common Stock | $1.02B | 98.88 | $36.34 | ▲ 0.03% | $18.8$36.46 |
| IVA Inventiva S.A. American Depository Shares | $1.10B | — | $2.94 | ▼ 5.47% | $2.57$6.2 |
| ANRO Alto Neuroscience Inc. Common Stock | $1.11B | — | $21.94 | ▼ 3.01% | $5.23$37.48 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Bank of America Puts These 2 Under-the-Radar IPO Stocks on Its Buy ListYahoo · 10/6/2026
- Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)Yahoo · 10/2/2026
- Was Moderna Stock's Cancer Vaccine Run Visible In Advance?Yahoo · 9/22/2026
- 12 Health Care Stocks Moving In Monday's Intraday SessionBenzinga · 9/21/2026
Insider Activity
Insider Actions →Acquired
1.22M
Disposed
18.10M
- Alpha Wave Ventures GP, Ltd · August 3, 2026 · Conversion0
- Alpha Wave Ventures GP, Ltd · August 3, 2026 · Conversion5.40M
- Alpha Wave Ventures GP, Ltd · August 3, 2026 · Conversion720.7K
- Alpha Wave Ventures GP, Ltd · August 3, 2026 · Conversion1.35M
- Alpha Wave Ventures GP, Ltd · August 3, 2026 · Conversion1.00M
- Morningside Venture Investments Ltd · August 3, 2026 · Conversion1.09M
- Morningside Venture Investments Ltd · August 3, 2026 · Conversion9.23M
- Morningside Venture Investments Ltd · August 3, 2026 · J75.6K
- Molnar Dennis Patrick · August 3, 2026 · Disposition12.2K
- Molnar Dennis Patrick · August 3, 2026 · Grant37.1K
- Molnar Dennis Patrick · August 3, 2026 · Disposition37.1K
- Molnar Dennis Patrick · August 3, 2026 · Grant28.5K
- Molnar Dennis Patrick · August 3, 2026 · Disposition28.5K
- Molnar Dennis Patrick · August 3, 2026 · Grant148.8K
- Molnar Dennis Patrick · August 3, 2026 · Disposition148.8K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Apnimed to Present Five Abstracts at CHEST 2026
Apnimed announced it will present five abstracts, including two late-breaking studies, at the CHEST 2026 conference. This highlights the company's ongoing research activity and clinical data generation. The stock currently trades well below its 52-week high, with an average analyst target of $50.33.
Apnimed to Present Five Abstracts at CHEST 2026. Apnimed announced it will present five abstracts, including two late-breaking studies, at the CHEST 2026 conference. This highlights the company's ongoing research activity and clinical data generation. The stock currently trades well below its 52-week high, with an average analyst target of $50.33.